文献リスト

1）Pompili M Saviano A, de Matthaeis N, et al. Long term effectiveness of resection and radiofrequency ablation for single hepatocellular carcinoma ≤3cm. Results of a multicenter Italian survey. J Hepatol. 2013; 59: 89-97

2）Feng K, Yan J, Li X, et al. A randomized controlled trial of radiofrequency ablation and surgical resection in the treatment of small hepatocellular carcinoma. J Hepatol. 2012; 57: 794-802

3）Hasegawa K, Kokudo N, Makuuchi M, et al. Comparison of resection and ablation for hepatocellular carcinoma: a cohort study based on a Japanese nationwide survey. J Hepatol. 2013; 58: 724-9

4）Shen A, Zhang H, Tang C, et al. A systemic review of radiofrequency ablation versus percutaneous ethanol injection for small hepatocellular carcinoma up to 3 cm. J Gastroenterol Hepatol. 2013; 28: 793-800

5）Osaki Y, Ikeda K, Izumi N, et al. Clinical effectiveness of bipolar radiofrequency ablation for small liver cancers. J Gastroenterol. 2013; 48: 874-83

6）Baldwin K, Katz SC, Rubin A, et al. Bipolar radiofrequency ablation of liver tumors: technical experience and interval follow-up in 22 patients with 33 ablations. J Surg Oncol. 2012; 106: 905-10

7）Makino Y, Imai Y, Ohama H, et al. Ultrasonography fusion imaging system increases the chance of radiofrequency ablation for hepatocellular carcinoma with poor conspicuity on conventional ultrasonography. Oncology. 2013; 84S: 44-50

8）Lee MW, Rhim H, Cha DI, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma: fusion imaging guidance for management of lesions with poor conspicuity at conventional sonograpgy. AJR Am J Roentgenol. 2012; 198: 1438-44

9）Toshikuni N, Takuma Y, Tomokuni J, et al. Needle electrode position assessed using three-dimensional ultrasonography and outcome of radiofrequency ablation in hepatocellular carcinoma. Hepatogastroenterology. 2013; 60: 428-31

10）Minami Y, Kudo M. Review of dynamic contrast-enhanced ultrasound guidance in ablation therapy for hepatocellular carcinoma. World J Gastroenterol. 2011; 17: 4925-9

11）Inoue T, Kudo M, Hatanaka K, et al. Usefullness of contrast-enhanced ultrasonography to evaluate the post-treatment responses of radiofrequency ablation for hepatocellular carcinoma: comparison with dynamic CT. Oncology. 2013; 84S: 51-7

12）Tomonari A, Tsuji K, Yamazaki H, et al. Feasibility of the virtual needle tracking system for percutaneous radiofrequency ablation of hepatocellular carcinoma. Hepatol Res. 2013; 43: 1352-5

13）Nishikawa H, Osaki Y, Iguchi E, et al. Radiofrequency ablation for hepatocellular carcinoma: the relationship between a new grading system for the ablative margin and clinical outcomes. J Gastroenterol. 2013; 48: 951-65

14）Lu Z, Wen F, Guo Q, et al. Radiofrequency ablation plus chemoenbolization versus radiofrequency ablation alone for hepatocellular carcinoma: a metaanalysis of randomized-controlled trials. Eur J Gastroenterol Hepatol. 2013; 25: 187-94

15）Mizukoshi E, Yamashita T, Arai K, et al. Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma. Hepatology. 2013; 57: 1448-57

16）Dan J, Zhang Y, Peng Z, et al. Postoperative neutrophil-to-lymphocyte ratio change predicts survival of patients with small hepatocellular carcinoma undergoing radiofrequency ablation. PLoS One. 2013; 8(3): e58184

17）Kim AY, Rhim H, Park M, et al. Venous thrombosis after radiofrequency ablation for hepatocellular carcinoma. AJR Am J Roentogenol. 2011; 197: 1476-80

18）Thein HH, Isaranuwatchai W, Campitelli MA, et al. Health care costs associated with hepatocellular carcinoma: A population-based study. Hepatology. 2013 in press. Doi: 10.1002/hep.26231

19）Forner A, Llovet JM, Bruix J. Chemoembolization for intermediate HCC: is there proof of survival benefit? J Hepatol. 2012; 56: 984-6

20）Burrel M, Reig M, Former A, et al. Survival of patients with hepatocellular bcarcinoma treated by transarterial chemoembolization (TACE) using drug eluting beads. Implications for clinical practice and trial design. J Hepatol. 2012; 56: 1330-5

21）Gao S, Yang Z, Zheng Z, et al. Doxorubicin-eluting beads versus conventional TACE for unresectable hepatocellular carcinoma: A meta-analysis. Hepatogastroenterology. 2013; 60: 126

22）Recchia F, Passalacqua G, Filauri P, et al. Chemoembolization of unresectable hepatocellular carcinoma: decreased toxicity with slow-release doxorubicin-eluting beads compared with lipiodol. Oncol Rep. 2012; 27: 1377-83

23）Song MJ, Chun HJ, Song do S, et al. Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma. J Hepatol. 2012; 57: 1244-50

24）Skowasch M, Schneider J, Otto G, et al. Midterm follow-up after DC-BEAD-TACE of hepatocellular carcinoma (HCC). Eur J Radiol. 2012; 81: 3857-61

25）Sottani C, Poggi G, Quaretti P, et al. Serum pharmacokinetics in patients treated with transarterial chemoembolization (TACE) using two types of epirubicin-loaded microspheres. Anticancer Res. 2012; 32: 1769-74

26）Takayasu K, Arii S, Kudo M, et al. Superselective transarterial chemoembolization for hepatocellular carcinjoma. Validation of treatment algorithm proposed by Japanese guidelines. J Hepatol. 2012; 56: 886-92

27）Shimohira M, Ogino H, Kawai T, et al. Clinical usefulness of the triaxial system in super-selective transcatheter arterial chemoembolization for hepatocellular carcinoma. Acta Radiol. 2012; 53: 857-61

28）Irie T, Kuramochi M, Takahashi N. Dense accumulation of lipiodol emulsion in hepatocellular carcinoma nodule during selective ballon-occluted transarterial chemoembolization: measurement of balloon-occluded arterial stump pressure. Cardiovascular Intervent Radiol. 2012. In press

29）Meyer T, Kirkwood A, Roughton M, et al. A randomized phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolization vs embolization alone for hepatocellular carcinoma. Br J Cancer. 2013; 108: 1252-9

30）Imai Y, Chikayama T, Nakazawa M, et al. Usefulness of miriplatin as an anticancer agent for transcatheter arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Gastroenterol. 2011. In press

31）Aramaki T, Moriguchi M, Bekku K, et al. Comparison of epirubicin hydrochloride and miriplatin hydrate as anticancer agents for transcatheter arterial chemoembolization of hepatocellular carcinoma. Hepatol Res. 2013; 43: 475-80

32）Iwazawa J, Ohue S, Hashimoto N, et al. Local tumor progression following lipiodol-based targeted chemoembolization of hepatocellular carcinoma: a retrospective comparison of miriplatin and epirubicin. Cancer Manag Res. 2012; 4: 113-9

33）Kora S, Urakawa H, Mitsufuji T, et al. Warming effect of miriplatin-lipiodol suspension for potential use as a chemotherapeutic agent for transarterial chemoembolization of hepatocellular carcinoma: In vitro study. Hepatol Res. 2013; 43: 1100-4

34）Seko Y, Ikeda Kawamura Y, et al. Antitumor efficacy of transcatheter arterial chemoembolization with warmed miriplatin in hepatocellular carcinoma. Hepatol Res. 2013; 43: 942-9

35）Imai N, Ikeda K, Seko Y, et al. Previous chemoembolization response after transcatheter arterial chemoembolization (TACE) can predict the anti-tumor effect of subsequent TACE with miriplatin in patients with recurrent hepatocellular carcinoma. Oncology. 2011; 80: 188-94

36）Sahara S, Kawai N, Sato M, et al. Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol. 2012; 35: 1363-71

37）Peng ZW, Guo RP, Zhang YJ, et al. Hepatic resection versus transcatheter arterial chemoembolization for the treatment of hepatocellular carcinoma with portal vein tumor thrombus. Cancer. 2012; 118: 4725-36

38）Hsu CY, Hsia CY, Huang YH, et al. Comparison of surgical resection and transarterial chemoembolization for hepatocellular carcinoma beyond the Milan criteria: a propensity score analysis. Ann Surg Oncol. 2012; 19: 842-9

39）Kaibori M, Tanigawa N, Kariya S, et al. A prospective randomized controlled trial of preoperative whole-liver chemolipiodolozation for hepatocellular carcinoma. Dig Dis Sci. 2012; 57: 1404-12

40）Kishi Y, Saiura A, Yamamoto J, et al. Preoperative transarterial chemoembolization for hepatocellular carcinoma. Hepatogastroenterology. 2012; 59: 2295-9

41）Zhou Y, Zheng X, Wu L, et al. Meta-analysis: preoperative transcatheter arterial chemoembolization does not improve prognosis of patients with resectable hepatocellular carcinoma. BMC Gastroenterol. 2013; 13: 51

42）Ke-Wei L, Tian-Fu W, Xi L, et al. The effect of postoperative TACE on prognosis of HCC with microscopic venous invasion. Hepatogastroenterology. 2012; 59: 1944-6

43）Kawaguchi T, Ohkawa K, Imanaka K, et al. Lipiodol accumulation and transarterial chemoembolization efficacy for HCC patients. Hepatogastroenterology. 2012; 59: 219-23

44）Kim DY, Ryu HJ, Choi JY, et al. Radiological response predicts survival following transarterial chemoembolization in patients with unresectable hepatocellular carcinoma. Aliment Phamacol Ther. 2012; 35: 1343-50

45）Imai N, Katano Y, Kuzuya T, et al. An increase in lesion density can predict lower local recurrence after transarterial chemoembolization in patients with hepatocellular carcinoma. Hepatogastroenterology. 2013; 60: 127

46）Kim HY, Park JW, Joo J, et al. Severity and timing of progression predict refratcoriness to transarterial chemoembolization in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012; 27: 1051-6

47）Bargellini I, Bozzi E, Campani D, et al. Modified RECIST to assess tumor response after transarterial chemoembolization of hepatocellular carcinoma: CT-pathologic correlation in 178 liver explants. Eur J Radiol. 2013; 82: e212-8

48）Shim JH, Lee HC, Won HJ, et al. Maximum number of target lesions requied to measure responses to transarterial chemoembolization using the enhancement criteria in patients with intrahepatic hepatocellular carcinoma. J Hepatol. 2012; 56: 406-11

49）Prajapati HJ, Spivey JR, Hanishi Si, et al. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE). Ann Oncol. 2013; 24: 965-73

50）Jung ES, Kim JH, Yoon EL, et al. Comparison of the methods for tumor response assessment in patients with hepatocellular carcinoma undergoing transarterial chemoembolization. J Hepatol. 2013. In press. Doi: 10.1016/j.hep.2013.01.039

51）Syha R, Ketelsen D, Heller S, et al. Hepatocellular carcinoma: initial tumour response after short-term and long-interval chemolipiodolization with drug-eluting beads using modified RECIST. Eur J Gastroenterol Hepatol. 2012; 24: 1325-32

52）Kim BK, Kim KA, Park JY, et al. Prospective comparison of prognostic values of modified response evaluation criteria in solid tumours with European Association for the Study of Liver criteria in hepatocellular carcinjoma following chemoembolization. Eur J Cancer. 2013; 49: 826-34

53）Sato Y, Watanabe H, Sone M, et al. Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIROSG-0602. Usp J Med Sci. 2013; 118: 16-22

54）Chung WS, Lee KH, Park MS, et al. Enhancement patterns of hepatocellular carcinoma after transarterial chemoembolization using drug-eluting beads on arterial phase CT images: a pilot retrospective study. AJR Am J Roentgenol. 2012; 199: 349-59

55）Loffroy R, Lin M, Yenokyan G, et al. Intraproceduredral C-arm dual-phase CT: can it be used to predict short-term response to TACE with drug-eluting beads in patients with hepatocellular carcinoma? Radiology. 3012; 266: 636-48

56）Moschouris H, Malagari K, Marinis A, et al. Hepatocellular carcinoma treated with transarterial chemoembolization: Evaluation with parametric contrast-enhanced ultrasonography. World J Radiol. 2012; 28: 379-86

57）Uller W, Wiggermann P, Gossmann H, et al. Evaluation of the microcirculation of hepatocellular carcinomas using contrast-enhanced ultrasound with intraarterial and intravenous contrast application during transarterial chemoembolization with drug-eluting beads (DEB-TACE): preliminary data. Clin Hemorheol Microcirc. 2011; 49: 55-66

58）Mannelli L, Kim S, Hajdu CH, et al. Serial diffusion-weighted MRI in patients with hepatocellular carcinoma: Prediction and assessment of response to transarterial chemoembolization. Preliminary experience. Eur J Radiol. 2013; 82: 577-82

59）Lee YK, Kim SU, Lim do Y, et al. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization. BMC Cancer. 2013; 3: 13

60）Wang Y, Chen Y, Ge N, et al. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization. Ann Surg Oncol. 2012; 19: 3540-6

61）Okabe N, Morimoto M, Kondo M, et al. Efficacy of chemoembolization for recurrent HCC after curative ablation therapy. Hepatogastroenterology. 2012; 29: 60

62）Terzi E, Golfiri R, Piscaglia F, et al. Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. J Hepatol. 2012; 57: 1258-67

63）Sieghart W, Hucke F, Pinter M, et al. The ART of decision making: retreatment with TACE in patients with hepatocellular carcinoma. Hepatology. 2013 in press. Doi: 10.1002/hep.26256

64）Kinugasa H, Nouso K, Takeuchi Y, et al. Risk factors for recurrence after transarterial chemoembolization for early-stage hepatocellular carcinoma. J Gastroenterol. 2012; 47: 421-6

65）Zhu CB, Wang C, Chen LL, et al. Serum YKL-40 independently predicts outcome after transcatheter arterial chemoembolization of hepatocellular carcinoma. PLoS One. 2012; 7: e44648

66）Guo JH, Zhu X, Li XT, et al. Impact of serum vascular endothelial growth factor on prognosis in patients with unresectable hepatocelllar carcinoma after transarterial chemoembolization. Chin J Cancer Res. 2012; 24: 36-43

67）Scartozzi M, Faloppi L, Bianconi R, et al. The role of LDH serum levels in predicting global outcome in HCC patiejnts undergoing TACE: implications for clinical management. PLoS One. 2012; 7: e32653

68）Saito M, Seo Y, Yano Y, et al. A high values of serum des-γ-carboxy prothrombin before hepatocellular carcinoma treatment can be associated with lon-term liver dysfunction after treatment. J Gastroenterol. 2012; 47: 1134-42

69）Guiu B, Deschamps F, Boulin M, et al. Serum gamma-glutamyl-transferase independently predicts outcome after transarterial chemoembolization of hepatocellular carcinoma: external validation. Cardiovasc Intervent Radiol. 2012; 35: 1102-8

70）Kohles N, Nagel D, Jungst D, et al. Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy. Tumor Biol. 2012; 33: 2401-9

71）McNally ME, Martinez A, Khabiri H, et al. Inflammatory markers are associated with outcome in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization. Ann Surg Oncol. 2013; 20: 923-8

72）Lu W, Li YH, He XF, et al. Transcatheter arterial chemoembolization enhances expression of Nm23-H1 and TIMP-2 in the tumor tissue of patients with hepatocellular carcinoma. Hepatogastroenterology. 2011; 58: 558-64

73）Jun CH, Ki HS, Lee HK, et al. Clinical significance and risk factors of postembolization fever in patients with hepatocellular carcinoma. World J Gastroenterol. 2013; 14: 284-9

74）Pomori M, Malagani K, Moschousis H, et al. Post embolization syndrome in doxorubicin eluting chemoembolization with DC bead. Hepatogastroenterology. 2012; 59: 820-5

75）Vogl TJ, Lammer J, Lencioni R, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. AJR Am J Roentgenol. 2011; 197: W562-70

76）Garwood ER, Fidelman N, Hoch SE, et al. Morbidity and mortality following transarterial liver chemoembolization in patients with hepatocellular carcinoma and synthetic dysfunction. Liver Transpl. 2013; 19: 164-73

77）Cho HS, Seo JW, Kang Y, et al. Incidence and risk factors for radiocontrast-induced nephropathy in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization. Clin Exp Nephrol. 2011; 15: 714-9

78）Nishikawa H, Osaki Y, Iguchi E, et al. Comparison of the efficacy of transcatheter arterial chemoembolization and sorafenib for advanced hepatocellular carcinoma. Exp Ther Med. 2012; 4: 381-6

79）Pinter M, Hucke F, Graziadei I, et al. Advanced-stage hepatocellular carcinoma: transarterial chemoembolization versus sorafenib. Radiology. 2012; 263: 590-9

80）Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolization in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer. 2011; 47: 2117-27

81）Park JW, Koh YH, Kim HB, et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012; 56: 1336-42

82）Chung TH, Han G, Yoon JH, et al. Interim analysis of START: study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial. Int J Cancer. 2013; 15: 2448-58

83）Qu XD, Chen CS, Wang JH, et al. The efficacy of TACE combined sorafenib in advanced stages hepatocellular carcinoma. BMC Cancer. 2012; 12: 263

84）Sansonno D, Lauletta G, Russi S, et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012; 17: 359-66

85）Pawlik TM, Reyes DK, Cosgrove IR, et al. Phase II trial of sorafenib combined with concurrent transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. J Clin Oncol. 2011; 29: 3960-7

86）Bai W, Wang YJ, Zhao Y, et al. Sorafenib in combination with transarterial chemoembolization improves the survival of patients with unresectable hepatocellular carcinoma: A propensity score matching study. J Dig Dis. 2013; 14: 181-90

87）Sieghart W, Pinter M, Reisegger M, et al. Conventional transarterial chemoembolization in combination with sorafenib for patients with hepatocellular carcinoma: a pilot study. Eur Radiol. 2012; 22: 1214-23

88）Ni JY, Liu SS, Xu LF, et al. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and RFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013; 139: 653-9

89）Ashoori N, Paprottka P, Trumm C, et al. Multimodality treatment with conventional transcatheter arterial chemoembolization and radiofrequency ablation for unresectable hepatocellular carcinoma. Digestion. 2012; 85: 18-26

90）Peng ZW, Zhang YJ, Liang HH, et al. Recurrent hepatocellular carcinoma treated with sequential transcatheter arterial chemoembolization and RF ablation versus RF ablation alone: a prospective randomized trial. Radiology. 2012; 262: 689-700

91）Honda Y, Kimura T, Aikata H, et al. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma. J Gastroenterol Hepatol. 2013; 28: 530-6

92）Kang JK, Kim MS, Cho CK, et al. Stereotactic body radiation therapy for inoperable hepatocellular carcinoma as a local salvage treatment after incomplete transarterial chemoembolization. Cancer. 2012; 118: 5424-31

93）Bruix J, Raoul JL, Sherman M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalysis of a phase III trial. J Hepatol. 2012; 57: 821-9

94）Raoul JL, Bruix J, Greten TF, et al. Relationship between baseline hepatic status and outcome, and effect of sorafenib on liver function: SHARP trial subanalyses. J Hepatol. 2012; 56: 1080-8

95）Worns MA, Koch S, Niederle IM, et al. The impact of patient and tumor baseline characteristics on the overall survival of patients with advanced hepatocellular carcinoma treated with sorafenib. Dig Liver Dis. 2013; 45: 408-13

96）Tsukui Y, Mochizuki H, Hoshino Y, et al. Factors contributing to the overall survival in patients with hepatocellular carcinoma treated by sorafenib. Hepatogastroenterology. 2012; 59: 2536-9

97）Personeni N, Bozzarelli S, Pressiani T, et al. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma. J Hepatol. 2012; 57: 101-7

98）Kuzuya T, Asahina Y, Tsuchiya K, et al. Early decrease in α-fetoprotein, but des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma. Oncology. 2011; 81: 251-8

99）Nakazawa T, Hidaka H, Takada J, et al. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Eur J Hastroenterol Hepatol. 2013; 25: 683-9

100）Kawaoka T, Aikata H, Murakami E, et al. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib. Oncology. 2012; 83: 192-200

101）Nakano M, Tanaka M, Kuromatsu R, et al. Efficacy, safety, and survival factors for sorafenib treatment in Japanese patients with advanced hepatocellular carcinoma. Oncology. 2013; 84: 108-14

102）Miyahara K, Nouso K, Morimoto Y, et al. Evaluation of the effect of sorafenib using serum NX-des-γ-carboxyprothrombin in patients with hepatocellular carcinoma. Hepatol Res. 2013; 43: 1064-70

103）Llovet JM, Pena CE, Lathia CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2012; 18: 2290-300

104）Shao YY, Huang CC, Lin SD, et al. Serum insulin-like growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy. Clin Cancer Res. 2012; 18: 3992-7

105）Frampas E, Lassau N, Zappa M, et al. Advanced hepatocellular carcinoma: early evaluation of response to targeted therapy and prognositic value of perfusion CT and dynamic contrast enhanced-ultrasound. Preliminary results. Eur J Radiol. 2013; 82: e205-11

106）Shiozawa K, Watanabe M, Kikuchi Y, et al. Evaluation of sorafenib for hepatocellular carcinoma by contrast-enhanced ultrasonography: a pilot study. World J Gastroenterol. 2012; 18: 5753-8

107）Sugimoto K, Moriyasu F, Saito K, et al. Hepatocellular carcinoma treated with sorafenib: early detection of treatment response and major adverse events by contrast-enhanced US. Liver Int. 2013; 33: 605-15

108）Kudo M, Ueshima K, Arizumi T. Real-life clinical practice with sorafenib in advanced hepatocellular carcinoma: a single-center experience. Dig Dis. 2012; 30: 609-16

109）Hagiwara S, Kudo M, Nagai T, et al. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma. Br J Cancer. 2012; 106: 1997-2003

110）Arao T, Ueshima K, Matsumoto K, et al. FGF3/FGF4 amplification and multiple lung metastasis in responders to sorafenib in hepatocellular carcinoma. Hepatology. 2013; 57: 1407-15

111）Di Costanzo GG, Tortora R, De Luca M, et al. Impact of age on toxicity and efficacy of sorafenib-targeted therapy in cirrhotic patients with hepatocellular carcinoma. Med Oncol. 2013; 30: 446

112）Wong H, Tang YF, Yao TJ, et al. The outcomes and safety of single-agent sorafenib in the treatment of elderly patients with advanced hepatocellular carcinoma (HCC). Oncologist. 2011; 16: 1721-8

113）Montella L, Addeo R, Cennamo G, et al. Sorafenib in elderly patients with advanced hepatocellular carcinoma: a case series. Oncology. 2013; 84: 265-72

114）Sposito C, Mariani L, Germini A, et al. Comparative efficacy of sorafenib vs. best supportive care in recurrent hepatocellular carcinoma after transplantation: a case-control study. J Hepatol. 2013; 59: 59-66

115）Camma C, Cabibbo G, Petta S, et al. Cost-effectiveness of sorafenib treatment in field practice for patients with hepatocellular carcinoma. Hepatology. 2013; 57: 1046-54

116）Cheng AL, Guan Z, Chen Z, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status: subset analyses of the phase III sorafenib Asia-Pacific trial. Eur J Cancer. 2012; 48: 1452-65

117）Otsuka T, Eguchi Y, Kawazoe S, et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012; 42: 879-86

118）Lee JH, Chung YH, Kim JA, et al. Genetic prediction of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma. Cancer. 2013; 119: 136-42

119）Duffy A, Wilkerson J, Greten TF. Hemorrhagic events in hepatocellular carcinoma patients treated with antiangiogenic therapies. Hepatology. 2013; 57: 1068-77

120）Koschny R, Gotthardt D, Koehler C, et al. Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma. Oncology. 2013; 84: 6-13

121）Brunocilla PR, Brunello F, Carucci P, et al. Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under conditions. Med Oncol. 2013; 30: 345

122）Nojiri K, Sugimoto K, Shiraki K, et al. Sorafenib and TRAIL have synergestic effect on hepatocellular carcinoma. Int J Oncol. 2013; 42: 101-8

123）Fang P, Hu JH, Cheng ZG, et al. Efficacy and safety of bevacizumab for the treatement of advanced hepatocellular carcinoma: a systemic review of phase II trials. PLoS One. 2012; 7: e49717

124）Zaanan A, Williet N, Hebbar M, et al. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. J Hepatol. 2013; 58: 81-8

125）Mir O, Coriat R, Boudou-Rouquette O, et al. Gemcitabine and oxaliplatin as second-line treatment in patients with hepatocellular carcinoma pre-treated with sorafenib. Med Oncol. 2012; 29: 2793-9

126）Dhooge M, Coriat R, Mir O, et al. Feasibility of gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma patients with Child-Pugh B cirrhosis. Oncology. 2013; 84: 32-8

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp